Global Cervix Conization Market – Industry Trends and Forecast to 2029

Cervix Conization Market Analysis and Size

The cervix conization market is expected to witness significant growth during the forecast period. According to global cancer statistics, nearly 80% of women's cases of cervical cancer occur in resource-poor developing countries. By the end of 2018, about 13,240 new cases of invasive cervical cancer will be diagnosed in the United States, and about 4,170 women will die of cervical cancer, according to the American Cancer Society. A good recovery approach is another important factor expected to support the number of screening tests in the estimated time frame. In addition, innovation is important in promoting accessibility and moderation of various analytical tests in the United States.

Data Bridge Market Research analyses a growth rate in the cervix conization market in the forecast period 2022-2029. The cervix conization market is expected to have a healthy CAGR in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Cervical conization, or cold knife cone (CKC), is a surgical procedure used to diagnose and treat cervical dysplasia, or very early stage cervical cancer. This involves removing the conical portion of the cervix to remove the cervical lesion along with the entire deformed zone. There are many indications for this procedure. Conflicts between Papanicolaou stain and biopsy findings, significantly milder histological findings than cytological findings, evidence of severe dysplasia, and presence of stage 1A1 squamous cell carcinoma.

Cervix Conization Market Scope and Segmentation

Global Cervix Conization Market Dynamics

Drivers

• Increasing Cervical Cancer

According to global cancer statistics, nearly 80% of women's cases of cervical cancer occur in resource-poor developing countries. Aside from lack of awareness, the difficulty of conducting cytopathological-based screening programs also plays a major role in delaying the treatment of cervical cancer in such economies, including India. Medical professionals attach great importance to robust pre-screening protocols that are essential for detecting early changes in the cervical epithelium.

• Rising Awareness of Cancer

The rising awareness about early diagnosis of cervical cancer is encouraging the adoption of HPV home testing kits that provide quick and accurate test results. 

Opportunities

• Adoption of Immunotherapy and Targeted Therapies

Immune-based therapies are touted as the most promising alternative therapies to prevent, treat, and treat cancer. Oncologists and medical professionals are expected to study immunotherapy's effectiveness in treating cervical cancer. These include checkpoint inhibitors that block the ability of cancer cells to damage the immune system and therapeutic vaccines that elicit a response to cancer cells. For instance, Axalimogene Filolisbac, which has already been studied in six clinical trials, is touted as the most unique immunotherapy for HPV-related cancers.

• Advanced Clinical Research and Technological Advancement

Increased clinical research and technological advancements are leading to market growth. The Curie Institute recently launched a new clinical trial called NiCOL focused on patients suffering from late-stage cervical cancer. With the aim of determining the optimal dose of nivolumab, a monoclonal antibody, researchers will evaluate the clinical efficacy of NiCOL, as well as the immunological and genetic mechanisms at the stage of pelvic chemoradiation therapy. On the other hand, Iovance Biotherapeutics, Inc, is a self-tumor infiltrating lymphocyte (TIL) LN-145 with the aim of providing recurrent metastatic and persistent, a second-line option for the treatment of cervical cancer.

Restraints/Challenges

• Lack of skilled professionals

The lack of qualified personnel who are unable to diagnose and treat the disease could curb the growth of the global cervix conization market over a forecast period.

• High cost

The huge expenditure required for diagnosing and treating the cervix cancer surely hamper the market growth.

This cervix conization market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cervix conization market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Cervix Conization Market

Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business. Its long-term repercussions are expected to influence industry growth during the forecast period. COVID-19 causes pneumonia, severe and acute respiratory illness, multiple organ failure, and, in severe cases, death. Older populations are more vulnerable to COVID-19. The pandemic killed about 342,000 women from cervical cancer in 2020.

In the post-pandemic era, COVID-19 is expected to positively impact the global cervix conization market, attributing to the increasing number of cervical cancer cases.

Global Cervix Conization Market Scope

The l cervix conization market is segmented on the basis of disease indication, age group and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease Indication

• Pre-malignant lesions
• Early invasive stage
• Advanced invasive stage

Age Group

• 20 to 35 years
• Above 35 years

End User

• Hospitals
• Diagnostic centers
• Cancer Palliative care clinics
• Pharmacies.

 Cervix Conization Market Regional Analysis/Insights

The cervix conization market is analysed and market size insights and trends are provided by disease indication, age group and end-user as referenced above.

The major countries covered in the cervix conization market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market in the forecast period due to the presence of key companies offering cervical cancer treatment, technological advancements, and increased number of health care centers.

Asia-Pacific is considered to have the most lucrative period due to the rise in cervical cancer prevalence and increased awareness in countries in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Global Cervix Conization Market Share Analysis

The cervix conization market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cervix conization market.

Key players operating in the cervix conization market include:

• Abbott (U.S.)
• Arbor Vita Corporation (U.S.)
• BD (U.S.)
• CooperSurgical Inc. (U.S.)
• F. Hoffmann-La Roche AG (U.S.)
• Guided Therapeutics Inc. (U.S.)
• Hologic Inc. (U.S.)
• QIAGEN (Germany)
• Quest Diagnostics Incorporated (U.S.)
• Siemens Healthcare GmbH (Germany)

SKU-68949